Clinical trials: Hypercalcemia
Osteoporosis, Humoral Hypercalcemia of Malignancy
One Week Parathyroid Hormone-related Protein (PTHrP) IV Dose Escalation Study
This is a dose escalation study to determine the maximum tolerable dose of Parathyroid Hormone-related Protein, PTHrP, that can be given safely over one week.
- Conditions
- Osteoporosis, Humoral Hypercalcemia of Malignancy, Hyperparathyroidism
- Trial name
- NCT00580788
- Testing
- PTHrP (1-36)
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Parathyroid Diseases, Parathyroid Dysfunction
Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy
The goal of this study is to assess whether using PTeye (AiBiomed, Santa Barbara, CA) - a NIRAF detection modality - can improve patient outcomes and reduce healthcare associated costs after parathyroid surgeries.
- Conditions
- Parathyroid Diseases, Parathyroid Dysfunction, Parathyroid Neoplasms, Parathyroid Adenoma
- Trial name
- NCT05152927
- Testing
- Parathyroid Eye (PTeye)
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- University of California, San Francisco
Parathyroid Adenoma, Parathyroid Neoplasms
Evaluating Impact of NIRAF Detection for Identifying Parathyroid Glands During Parathyroidectomy
This study describes a single center, randomized, single-blinded clinical trial to assess the clinical benefits of the use of near infrared autofluorescence (NIRAF) detection with an FDA-cleared device 'Parathyroid Eye (PTeye)'…
- Conditions
- Parathyroid Adenoma, Parathyroid Neoplasms, Parathyroid Hyperplasia, Parathyroid Cancer
- Trial name
- NIRAF (NCT04299425)
- Testing
- NIRAF Detection Technology
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Sarcoidosis, Hypercalcemia Due to Sarcoidosis
ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study
ACTHAR Gel has activity in sarcoidosis associated hypercalciuria and calcium dysregulation.
- Trial name
- NCT02155803
- Testing
- ACTHAR Gel (adrenocorticotropic hormone)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Albany Medical College
Kidney Failure, Secondary Hyperparathyroidism
Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol
The purpose of this non-inferiority study is to compare the safety and effectiveness of a mineral and bone disease treatment protocol based on calcitriol to one based on paricalcitol in hemodialysis patients using revised Kidney…
- Conditions
- Kidney Failure, Secondary Hyperparathyroidism, Hyperphosphatemia, Hypercalcemia
- Trial name
- ECRIP (NCT01725113)
- Testing
- Calcitriol, Paricalcitol
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Winthrop University Hospital
Hypercalcemia of Malignancy, Lung Cancer
Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone
RATIONALE: Zoledronate may help to relieve some of the symptoms caused by bone metastases. It is not yet known if zoledronate is more effective than no further therapy in relieving symptoms of bone metastases or preventing…
- Conditions
- Hypercalcemia of Malignancy, Lung Cancer, Metastatic Cancer, Pain
- Trial name
- NCT00003884
- Testing
- zoledronic acid, quality-of-life assessment
- Where
- 55 sites in United States
- Volunteers
- 600 people
- Sponsor
- Novartis
Hypercalcemia, Hyperparathyroidism
The Novel Approach of Minimally Invasive Parathyroid Surgery Requires Precise Identification and Localization of the Lesion Prior to Exploration
Purpose of this study is to compare the image quality and diagnostic accuracy obtained with ultrafast solid state short SPECT in comparison with the routine SPECT protocol.
- Trial name
- NCT01226810
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Rambam Health Care Campus
Comorbidities and Coexisting Conditions, Morality
Registry for Hypoparathyroidism Wuerzburg
Long-term conventional treatment of chronic hypoparathyroidism does not fully restore calcium homeostasis leading to increased morbidity, emergency events and reduced subjective health status.
- Conditions
- Comorbidities and Coexisting Conditions, Morality, Hypocalcemia, Hypercalcemia
- Trial name
- NCT05585593
- Where
- Germany
- Volunteers
- 300 people
- Sponsor
- University of Wuerzburg
Hyperparathyroidism, Primary, Osteoporosis
Efficacy of Cinacalcet in the Control of Primary Hyperparathyroidism
To assess the efficacy and safety of treatment with cinacalcet and with cinacalcet plus alendronate in controlling bone loss induced by primary hyperparathyroidism.
- Trial name
- CA-PHP (NCT02417389)
- Testing
- cinacalcet, Alendronate
- Where
- Italy
- Volunteers
- 22 people
- Sponsor
- Istituto Auxologico Italiano
Parathyroid Carcinoma, Hypercalcemia
An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism
This is an intra-individual titration study of KRN1493 to evaluate the safety and efficacy of KRN1493 for the treatment of hypercalcemia in patients with parathyroid carcinoma or intractable primary hyperparathyroidism (PHPT).
- Conditions
- Parathyroid Carcinoma, Hypercalcemia, Primary Hyperparathyroidism
- Trial name
- NCT01460030
- Testing
- Cinacalcet HCl
- Where
- Japan
- Sponsor
- Kyowa Kirin Co., Ltd.
Vitamin D Deficiency, Primary Hyperparathyroidism
Effect of Vitamin D Treatment in Primary Hyperparathyroidism
The primary aim of the study is to assess whether 6-months of vitamin D supplements can decrease PTH compared with placebo treatment in primary hyperparathyroidism.
- Conditions
- Vitamin D Deficiency, Primary Hyperparathyroidism, Hypercalcemia
- Trial name
- NCT00674154
- Testing
- Cholecalciferol
- Where
- Denmark
- Volunteers
- 46 people
- Sponsor
- University of Aarhus
Diabetes, Cancer
Family Genetics Health Education and Healthy Behaviors
Background: Family-based approaches to reduce disease risk and promote healthy behaviors may be better than targeting individuals.
- Conditions
- Diabetes, Cancer, Heart Disease
- Trial name
- NCT01498276
- Where
- 2 sites in United States
- Volunteers
- 310 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Breast Cancer, Hypercalcemia of Malignancy
Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone Metastases
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Zoledronate may prevent bone loss and stop the growth of tumor cells in bone.
- Conditions
- Breast Cancer, Hypercalcemia of Malignancy, Metastatic Cancer, Pain
- Trial name
- NCT00060138
- Testing
- monoclonal antibody CAL, zoledronic acid
- Where
- United States
- Sponsor
- Chugai Pharmaceutical
Secondary Hyperparathyroidism, End-Stage Renal Disease
Study to Evaluate Safety of Vitamin D Receptor Activators in Patients Ages 0 to 16 With Chronic Kidney Disease Stage 5 Receiving Peritoneal Dialysis Within Current Clinical Practice
The objective of this study was to observe the safety of paricalcitol utilization in pediatric participants (ages 0 to 16 years old) being treated for secondary hyperparathyroidism (SHPT).
- Trial name
- NCT01134315
- Testing
- Paricalcitol, Calcitriol
- Where
- 18 sites in United States
- Volunteers
- 61 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Secondary Hyperparathyroidism, Hypercalcemia
Cinacalcet to Treat Hypercalcemia in Renal Transplant Recipients
Secondary hyperparathyroidism can persist following successful renal transplantation and can cause high blood calcium, kidney dysfunction or failure and excessive bone loss among other problems.
- Trial name
- NCT00415584
- Testing
- Cinacalcet HCl
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Montefiore Medical Center
Breast Cancer, Hypercalcemia of Malignancy
S0308 Zoledronate or Ibandronate in Preventing Bone Problems in Women With Stage IV Breast Cancer That Has Spread to the Bone
RATIONALE: Zoledronate and ibandronate may prevent or help relieve bone pain and other symptoms caused by bone metastases. It is not yet known whether zoledronate is more effective than ibandronate in preventing bone problems…
- Conditions
- Breast Cancer, Hypercalcemia of Malignancy, Metastatic Cancer, Pain
- Trial name
- NCT00301886
- Testing
- ibandronate, zoledronate, quality-of-life assessment
- Sponsor
- SWOG Cancer Research Network
Breast Neoplasms, Breast Cancer
An Investigational Drug (CAL) Versus Zoledronic Acid (Zometa®) in Patients With Breast Cancer
This study is intended to evaluate the safety, tolerability, and possible effectiveness of an investigational humanized monoclonal antibody (CAL) to the parathyroid hormone-related protein (PTHrP) when compared to zoledronic acid…
- Conditions
- Breast Neoplasms, Breast Cancer, Metastasis
- Trial name
- NCT00051779
- Testing
- CAL
- Where
- 38 sites in United States
- Sponsor
- Chugai Pharma USA
Secondary Hyperparathyroidism
Parathyroidectomy vs Cinacalcet in the Treatment of Secondary Hyperparathyroidism Post Renal Transplantation
The hypothesis of this study is that subtotal parathyroidectomy using minimally invasive surgery is superior to cinacalcet for the treatment of persistent secondary hyperparathyroidism (HPT) post renal transplant, with minimal…
- Trial name
- NCT01178450
- Testing
- Subtotal parathyroidectomy, Cinacalcet
- Where
- 2 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Josep M Cruzado
Osteoporosis, Hypercalcemia
Evaluation of the Role of Luteinizing Hormone (LH) and Human Chorionic Gonadotropin (hCG) in Adult Patients Undergoing Assessment for Endocrine Disorders
Hormones are chemical messengers that help regulate many functions in the body. As women go through menopause, and as men age, levels of certain reproductive hormones change significantly.
- Conditions
- Osteoporosis, Hypercalcemia, Primary Hyperparathyroidism, Adrenal Gland Disease
- Trial name
- NCT07824102
- Where
- Denmark
- Volunteers
- 20,000 people
- Sponsor
- Martin Blomberg Jensen
Hyperparathyroidism
The Effects of Alendronate After Cure of Primary Hyperparathyroidism
We are investigating whether, after surgical cure of primary hyperparathyroidism, alendronate provides even greater beneficial skeletal effects than parathyroidectomy alone.
- Trial name
- AlenPostPara (NCT00359385)
- Testing
- Alendronate 70mg weekly
- Where
- United States
- Sponsor
- Columbia University